Blog
RSS FeedPosted by Michael Wonder on 05 Dec 2016
PHARMAC funds breast cancer drug Perjeta
5 December 2016 - More breast cancer sufferers will soon have access to a treatment programme that can extend lives ...
Posted by Michael Wonder on 04 Dec 2016
Approval of multi-product funding proposal with Roche
5 December 2016 - PHARMAC is pleased to announce a major funding package following an agreement with Roche for funding ...
Posted by Michael Wonder on 30 Nov 2016
New Zealand Pharmaceutical Schedule - 1 December 2016
1 December 2016 - The December 2016 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 24 Nov 2016
Petition to pressure PHARMAC over HIV meds
24 November 2016 - Three years after a irrefutable case was made by HIV organisations and specialists the NZAF is reporting ...
Posted by Michael Wonder on 16 Nov 2016
Proposal to list oral betaine for rare disorder
16 November 2016 - PHARMAC is seeking feedback on a proposal to list betaine (Cystadane) resulting from a provisional agreement ...
Posted by Michael Wonder on 14 Nov 2016
Decision to list enzyme replacement therapies for some rare disorders
11 November 2016 - PHARMAC is pleased to announce the approval of an agreement with Sanofi-Aventis for the listing of ...
Posted by Michael Wonder on 31 Oct 2016
New Zealand Pharmaceutical Schedule - 1 November 2016 update
1 November 2016 - The November 2016 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 31 Oct 2016
Proposal to list and award sole supply to celecoxib Pfizer
31 October 2016 - Following a request for proposals for the supply of selective cyclooxygenase-2 inhibitors of the ‘coxib’ class ...
Posted by Michael Wonder on 28 Oct 2016
PHARMAC outlines changes at Tauranga public forum
27 October 2016 - Pharmac came to Tauranga yesterday to discuss proposed changes to improve how medicines and medical device funding ...
Posted by Michael Wonder on 28 Oct 2016
Update on proposed changes to 2nd & 3rd line anti-VEGF treatments for ophthalmic use
28 October 2016 - On 5 September 2016, PHARMAC consulted on a proposal to list ranibizumab (Lucentis) and aflibercept (Eylea) ...
Posted by Michael Wonder on 27 Oct 2016
New Zealanders to benefit from partnership to enhance responsible use of medicines
27 October 2016 - PHARMAC is pleased to announce a new partnership to support prescribing decisions and promote the responsible ...
Posted by Michael Wonder on 25 Oct 2016
All clear for Hep C after Australian medication
25 October 2016 - In January Hamilton News reported on Julie, a Cambridge woman diagnosed with hepatitis C who sourced ...
Posted by Michael Wonder on 25 Oct 2016
Asbestos cancer patient seeking Government funding
25 October 2016 - A cancer patient is pleading with the Government to fund treatment for everyone exposed to asbestos. ...
Posted by Michael Wonder on 23 Oct 2016
Woman battling rare cancer gets PHARMAC funding for drug
24 October 2016 - A young woman with a body riddled with fast growing tumours, who was left in a ...
Posted by Michael Wonder on 17 Oct 2016
Decision to list cholic acid (Cholebiol) for rare disorder
17 October 2016 - PHARMAC is pleased to announce the approval of an agreement with Max Health Limited for the ...